| |
Derivation (group A)
|
Validation (group B)
|
|---|
|
n
|
RA
|
n
|
RA
|
|---|
|
Age (years, mean ± SD)
|
87
|
56.1 ± 13.8
|
88
|
57.3 ± 14.2
|
|
Female (%)
|
87
|
64 (73.6)
|
88
|
66 (75)
|
|
Serology n (%)
|
|
CCP positive
|
74
|
52 (70.3)
|
78
|
57 (73.1)
|
|
RF positive
|
82
|
48 (58.5)
|
85
|
53 (62.4)
|
|
CRPb (mg/L)
|
63
|
10.91 ± 22.73
|
74
|
7.24 ± 11.86
|
|
Tobacco n (%)
|
85
|
22 (25.9)
|
82
|
19 (23.5)
|
|
Disease duration (years)
|
88
|
11.6 ± 5.8
|
89
|
10.3 ± 6.1
|
|
Active diseasea n (%)
|
81
|
42 (51.9)
|
82
|
37 (45.1)
|
|
RAPID-3 scoresc
|
71
|
27 (38)
|
67
|
24 (35.8)
|
|
Erosions
|
82
|
27 (32.9)
|
84
|
25 (29.8)
|
|
Subcutaneous nodules
|
84
|
11 (13.1)
|
88
|
9 (10.2)
|
|
ILDd
|
87
|
4 (4.6)
|
89
|
3 (3.4)
|
|
Current treatment n (%)
|
|
Biologics
|
86
|
36 (41.9)
|
85
|
33 (38.8)
|
|
DMARDe
|
85
|
78 (91.8)
|
86
|
78 (90.7)
|
|
Prednisone > 5 mg
|
85
|
6 (7.1)
|
85
|
7 (8.2)
|
|
Biologics ever
|
84
|
42 (50)
|
85
|
41 (48.2)
|
-
aActive disease: defined as presence of at least one swollen joint
-
b
CRP C-reactive protein, c
RAPID routine assessment of patient index data, d
ILD interstitial lung disease, e
DMARD disease-modifying antirheumatic drug
